Leukotriene Receptor Antagonists (LTRAs) are a class of medications designed to mitigate the effects of leukotrienes, inflammatory mediators involved in various allergic and inflammatory conditions. Leukotrienes are lipid compounds produced by cells, particularly in response to allergens, and play a pivotal role in bronchoconstriction, inflammation, and mucus production. LTRAs function by selectively blocking the receptors to which leukotrienes bind, particularly the cysteinyl leukotriene receptors. By doing so, LTRAs disrupt the signaling cascade that leads to the inflammatory responses associated with conditions like asthma and allergic rhinitis. As a result, these antagonists help alleviate symptoms such as bronchoconstriction and airway inflammation, making them valuable in the management of chronic respiratory conditions. Montelukast and zafirlukast are prominent examples of LTRAs, often prescribed as maintenance therapy for asthma and as adjuncts in allergic rhinitis. LTRAs are recognized for their oral administration, convenience, and effectiveness in certain individuals, especially those with mild to moderate asthma. While generally well-tolerated, potential side effects include gastrointestinal disturbances. Leukotriene Receptor Antagonists have become integral components in the therapeutic arsenal against allergic and inflammatory diseases, offering targeted relief and improved quality of life for affected individuals.
